---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-066416"
form_type: "8-K"
ticker: "ARTV"
cik: "0001817241"
company_name: "Artiva Biotherapeutics, Inc."
filed_at: "2025-05-08T23:59:59+00:00"
generated_at: "2026-05-22T05:17:51.783432+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Artiva reports Q1 net loss $20.3M; AlloNK IND cleared for autoimmune basket trial

## Summary
- Cash, cash equivalents and investments of $166.0M as of March 31, 2025; cash runway into Q2 2027.
- R&D expenses $17.1M (vs $11.2M YoY); net loss $20.3M (vs $14.0M YoY).
- IND cleared for Phase 2a basket trial of AlloNK+rituximab in refractory RA, Sjögren's, myositis, scleroderma; site initiation underway.
- Longer-term B-NHL data at ASGCT shows CR rates and median DOR in line with approved auto-CAR-T therapies.
- Appointed Subhashis Banerjee, M.D. as CMO on April 8, 2025.

## SEC filing metadata
- accession: 0000950170-25-066416
- form_type: 8-K
- ticker: ARTV
- cik: 0001817241
- company_name: Artiva Biotherapeutics, Inc.
- filed_at: 2025-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1817241/000095017025066416/0000950170-25-066416-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1817241/000095017025066416/artv-20250508.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-066416
- JSON: https://secwatch.observer/filing/0000950170-25-066416.json
- Plain text: https://secwatch.observer/filing/0000950170-25-066416.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.